vs
摩根士丹利（MS）与辉瑞（PFE）财务数据对比。点击上方公司名可切换其他公司
摩根士丹利的季度营收约是辉瑞的1.0倍（$17.9B vs $17.6B），摩根士丹利净利率更高（24.6% vs -9.4%，领先34.0%）
摩根士丹利是总部位于美国纽约曼哈顿中城百老汇1585号的跨国投资银行及金融服务提供商，在全球42个国家设有办事处，员工超8万名，服务客户涵盖企业、政府、机构及个人。2023年该公司位列美国财富500强第61位，同年位居福布斯全球2000强第30位。
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
MS vs PFE — 直观对比
营收规模更大
MS
是对方的1.0倍
$17.6B
净利率更高
MS
高出34.0%
-9.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.9B | $17.6B |
| 净利润 | $4.4B | $-1.6B |
| 毛利率 | — | 70.0% |
| 营业利润率 | 32.2% | -9.4% |
| 净利率 | 24.6% | -9.4% |
| 营收同比 | — | -1.2% |
| 净利润同比 | — | -501.7% |
| 每股收益（稀释后） | $2.68 | $-0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSPFE
| Q4 25 | $17.9B | $17.6B | ||
| Q3 25 | $18.2B | $16.7B | ||
| Q2 25 | $16.8B | $14.7B | ||
| Q1 25 | $17.7B | $13.7B | ||
| Q4 24 | — | $17.8B | ||
| Q3 24 | $15.4B | $17.7B | ||
| Q2 24 | $15.0B | $13.3B | ||
| Q1 24 | $15.1B | $14.9B |
净利润MSPFE
| Q4 25 | $4.4B | $-1.6B | ||
| Q3 25 | $4.6B | $3.5B | ||
| Q2 25 | $3.5B | $2.9B | ||
| Q1 25 | $4.3B | $3.0B | ||
| Q4 24 | — | $410.0M | ||
| Q3 24 | $3.2B | $4.5B | ||
| Q2 24 | $3.1B | $41.0M | ||
| Q1 24 | $3.4B | $3.1B |
毛利率MSPFE
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 74.9% | ||
| Q2 25 | — | 74.2% | ||
| Q1 25 | — | 79.3% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | — | 70.3% | ||
| Q2 24 | — | 75.2% | ||
| Q1 24 | — | 77.3% |
营业利润率MSPFE
| Q4 25 | 32.2% | -9.4% | ||
| Q3 25 | 33.1% | 20.0% | ||
| Q2 25 | 27.5% | 20.8% | ||
| Q1 25 | 31.3% | 20.3% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | 27.4% | 26.6% | ||
| Q2 24 | 27.1% | -0.8% | ||
| Q1 24 | 29.0% | 23.0% |
净利率MSPFE
| Q4 25 | 24.6% | -9.4% | ||
| Q3 25 | 25.3% | 21.3% | ||
| Q2 25 | 21.1% | 19.9% | ||
| Q1 25 | 24.3% | 21.6% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 20.7% | 25.2% | ||
| Q2 24 | 20.5% | 0.3% | ||
| Q1 24 | 22.5% | 20.9% |
每股收益（稀释后）MSPFE
| Q4 25 | $2.68 | $-0.29 | ||
| Q3 25 | $2.80 | $0.62 | ||
| Q2 25 | $2.13 | $0.51 | ||
| Q1 25 | $2.60 | $0.52 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $1.88 | $0.78 | ||
| Q2 24 | $1.82 | $0.01 | ||
| Q1 24 | $2.02 | $0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $111.7B | $1.1B |
| 总债务越低越好 | $341.7B | — |
| 股东权益账面价值 | $111.6B | $86.5B |
| 总资产 | $1420.3B | $208.2B |
| 负债/权益比越低杠杆越低 | 3.06× | — |
8季度趋势，按日历期对齐
现金及短期投资MSPFE
| Q4 25 | $111.7B | $1.1B | ||
| Q3 25 | $103.7B | $1.3B | ||
| Q2 25 | $109.1B | $1.6B | ||
| Q1 25 | $90.7B | $1.4B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $91.1B | $1.1B | ||
| Q2 24 | $90.2B | $1.1B | ||
| Q1 24 | $102.3B | $719.0M |
总债务MSPFE
| Q4 25 | $341.7B | — | ||
| Q3 25 | $324.1B | — | ||
| Q2 25 | $320.1B | — | ||
| Q1 25 | $297.0B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $291.2B | — | ||
| Q2 24 | $269.9B | — | ||
| Q1 24 | $266.1B | — |
股东权益MSPFE
| Q4 25 | $111.6B | $86.5B | ||
| Q3 25 | $110.0B | $92.8B | ||
| Q2 25 | $108.2B | $88.7B | ||
| Q1 25 | $106.8B | $90.3B | ||
| Q4 24 | — | $88.2B | ||
| Q3 24 | $103.6B | $92.3B | ||
| Q2 24 | $100.7B | $87.7B | ||
| Q1 24 | $99.2B | $92.3B |
总资产MSPFE
| Q4 25 | $1420.3B | $208.2B | ||
| Q3 25 | $1364.8B | $208.7B | ||
| Q2 25 | $1353.9B | $206.1B | ||
| Q1 25 | $1300.3B | $208.0B | ||
| Q4 24 | — | $213.4B | ||
| Q3 24 | $1258.0B | $219.5B | ||
| Q2 24 | $1212.4B | $216.2B | ||
| Q1 24 | $1228.5B | $221.1B |
负债/权益比MSPFE
| Q4 25 | 3.06× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 2.96× | — | ||
| Q1 25 | 2.78× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.81× | — | ||
| Q2 24 | 2.68× | — | ||
| Q1 24 | 2.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4B | $5.3B |
| 自由现金流经营现金流 - 资本支出 | — | $4.5B |
| 自由现金流率自由现金流/营收 | — | 25.6% |
| 资本支出强度资本支出/营收 | — | 4.8% |
| 现金转化率经营现金流/净利润 | -0.55× | — |
| 过去12个月自由现金流最近4个季度 | — | $9.1B |
8季度趋势，按日历期对齐
经营现金流MSPFE
| Q4 25 | $-2.4B | $5.3B | ||
| Q3 25 | $-3.3B | $4.6B | ||
| Q2 25 | $11.8B | $-582.0M | ||
| Q1 25 | $-24.0B | $2.3B | ||
| Q4 24 | — | $6.7B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $-1.8B | ||
| Q1 24 | $4.4B | $1.1B |
自由现金流MSPFE
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $-1.2B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $-2.4B | ||
| Q1 24 | — | $386.0M |
自由现金流率MSPFE
| Q4 25 | — | 25.6% | ||
| Q3 25 | — | 24.0% | ||
| Q2 25 | — | -8.2% | ||
| Q1 25 | — | 12.9% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 34.3% | ||
| Q2 24 | — | -18.2% | ||
| Q1 24 | — | 2.6% |
资本支出强度MSPFE
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | 4.7% |
现金转化率MSPFE
| Q4 25 | -0.55× | — | ||
| Q3 25 | -0.72× | 1.30× | ||
| Q2 25 | 3.34× | -0.20× | ||
| Q1 25 | -5.56× | 0.79× | ||
| Q4 24 | — | 16.39× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | -43.44× | ||
| Q1 24 | 1.28× | 0.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MS
暂无分部数据
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
